Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
Screen a stock
TERMINAL
VR

VRCAStockVerrica Pharmaceuticals Inc

NASDAQ NMS - GLOBAL MARKET · Healthcare · US

$2.74 last close 2026-11-20
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment VRCA's does — no target price to set, unlike a price alert.

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-12
Assessed 2026-08-12
0 of 3 pass our own screen — 4 of 7 could not be computed
HTR non-permissible income 2.61%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
🟠 NOT YET
The main driver: lagging the market by 16.8%. More negatives than positives right now. The setup isn't ready — check...
Scores: 1 bullish / 2 bearish

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

GAP · SCALP
Entry
$5.07
Stop
$4.96
Target
$5.29
Risk : Reward 2.0R

Verrica Pharmaceuticals Inc (VRCA) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 435 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
BUY
13 analysts
Institutional own.
27.1%
of shares
2.61%
Non-permissible income — HTR, from filings (2025-12-31)
BUY
Wall Street consensus (13)
27.1%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to VRCA’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

  • Nov 21, 2026 Non-compliant → Compliantour daily record began reading this page's own headline on this date; the page's status did not change here
  • Nov 20, 2026 Not rated → Non-compliant0 of 3 decided standards pass; figures as of Sep 30, 2026
  • Nov 17, 2026 Tracking began Nothing before this date is on record.

Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $57.5M as of 2026-11-19.

Business activity: cleared (no excluded categories detected)

AAOIFI Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 2 of 3 computed, both pass
RatioValueThresholdResult
Interest-bearing debt
debt not reported
not available 30.00% Unverified
Interest-bearing investments 25.47% 30.00% Pass(4.5pp buffer)
Non-permissible income 2.61% 5.00% Pass(2.4pp buffer)
Usmani Fail 4 of 5 computed, 3 pass, 1 fails
RatioValueThresholdResult
Interest-bearing debt
debt not reported
not available 33.00% Unverified
Interest-bearing investments 36.77% 33.00% Fail(3.8pp over)
Non-liquid assets 35.04% at least 20.00% Pass(15.0pp above the floor)
Non-permissible income 2.61% 5.00% Pass(2.4pp buffer)
Net liquid assets per share $4.0M under mkt cap $57.5M Pass
MSCI Fail 3 of 4 computed, 1 passes, 2 fail
RatioValueThresholdResult
Interest-bearing debt
debt not reported
not available 33.33% Unverified
Cash + interest-bearing securities 36.77% 33.33% Fail(3.4pp over)
Accounts receivable 64.96% 33.33% Fail(31.6pp over)
Non-permissible income 2.61% 5.00% Pass(2.4pp buffer)
FTSE Fail 3 of 4 computed, 1 passes, 2 fail
RatioValueThresholdResult
Interest-bearing debt
debt not reported
not available 33.33% Unverified
Cash + interest-bearing securities 36.77% 33.33% Fail(3.4pp over)
Accounts receivable 64.96% 50.00% Fail(15.0pp over)
Non-permissible income 2.61% 5.00% Pass(2.4pp buffer)
Dow Jones Islamic Market Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 3 of 4 computed, all pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt
debt not reported
not available 33.00% Unverified
Cash + interest-bearing securities 16.76% 33.00% Pass(16.2pp buffer)
Accounts receivable 12.85% 33.00% Pass(20.1pp buffer)
Non-permissible income 2.61% 5.00% Pass(2.4pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt (bound) at most 31.23% 33.00% Pass
Cash + interest-bearing securities 9.99% 49.00% Pass(39.0pp buffer)
Accounts receivable 7.66% 49.00% Pass(41.3pp buffer)
Non-permissible income 2.61% 5.00% Pass(2.4pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt (bound) at most 31.23% 33.33% Pass
Cash + interest-bearing securities 9.99% 33.33% Pass(23.3pp buffer)
Accounts receivable 17.64% 49.00% Pass(31.4pp buffer)
Non-permissible income 2.61% 5.00% Pass(2.4pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)non permissible income ratio 2.4pts
S&P Shariah Indices (% of 36-mo avg market cap)non permissible income ratio 2.4pts
MSCI Islamic Index (% of total assets)non permissible income ratio 2.4pts
MSCI Islamic Index (% of total assets)receivables ratio 31.6pts
FTSE Shariah Global Equity Index Series (% of total assets)receivables ratio 15.0pts
Usmani (% of total assets)investments ratio 3.8pts

The numbers the ratios are built from

Read from VRCA's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $35.6M 2025-12-31 Revenues
Interest-bearing debtBorrowings — which definition was stored is not recorded not measured — —
Cash and interest-bearing securitiesCash, equivalents and marketable securities $14.7M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $39.9M 2026-09-30 Assets
Market capDenominator for AAOIFI $57.5M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $116.0M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $65.1M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $929.0K 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-13, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-03-11, period ended 2025-12-31. Screened 2026-11-19.

  • Total assets$39.9M
    Assets · period ended 2026-09-30 · 10-Q filed 2026-11-13
  • Cash and interest-bearing securities$14.7M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · period ended 2026-09-30 · 10-Q filed 2026-11-13
  • Receivables$11.2M
    AccountsReceivableNetCurrent · period ended 2026-09-30 · 10-Q filed 2026-11-13
  • Revenue$35.6M
    Revenues · period ended 2025-12-31 · 10-K filed 2026-03-11
  • Interest income (non-permissible)$929.0K
    InvestmentIncomeInterest · period ended 2025-12-31 · 10-K filed 2026-03-11
  • Market cap$57.5M
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-19 · not a filing figure, so no link

5 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for VRCA. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-19 Unverified → Fail filing re-screen

Tracked since 2026-09-07.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Tracked investors holding VRCA
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $0M 0.0% 2026-09-30
Peter Brown Renaissance Technologies $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

9.107.515.924.332.742025-11-242026-05-272026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
2.30
S2
2.53
S1
2.71
PIVOT
2.95
R1
3.12
R2
3.36
R3
3.53

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
3.62 – 5.12
±17.24% from 4.37, made 2026-09-27 · resolves 2026-10-04
STRONG SELL
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)34.00NEUTRAL
Stochastic %K (14)0.68BUY
CCI (20)-185.64BUY
Williams %R (14)-99.32BUY
MACD (12,26,9)-0.04SELL
ROC (10)-14.11SELL
Momentum (10)-0.45SELL
EMA (10)3.15SELL
SMA (10)3.31SELL
EMA (20)3.34SELL
SMA (20)3.32SELL
EMA (30)3.50SELL
SMA (30)3.44SELL
EMA (50)3.81SELL
SMA (50)3.85SELL
EMA (100)4.44SELL
SMA (100)4.61SELL
EMA (200)5.28SELL
SMA (200)5.30SELL

About Verrica Pharmaceuticals Inc

Healthcare · Biotechnology

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

verrica.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-08-28

GAP
Type · SCALP
5.07
Entry
4.96
Stop
5.29
Target
WIN
Outcome · exit 5.29 (+4.34%)

Stop 4.96 Now 2.74 Target 5.29

Verdict

🟠 NOT YET

The main driver: lagging the market by 16.8%. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.

Scores: 1 bullish / 2 bearish

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

Still fetching the market-structure read — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.